Vasopressin SNP pain factors and stress in sickle cell disease

English version

Autoři: Keesha L. Powell-Roach ^aff001; Yingwei Yao ^aff003; Ellie H. Jhun ^aff005; Ying He ^aff006; Marie L. Suarez ^aff004; Miriam O. Ezenwa ^aff003; Robert E. Molokie ^aff006; Zaijie Jim Wang ^aff006; Diana J. Wilkie ^aff002
Působiště autorů: Department of Community Dentistry and Behavioral Science, College of Dentistry, University of Florida, Gainesville, Florida, United States of America ^aff001; Center for Palliative Care Research and Education, University of Florida College of Nursing, Gainesville, Florida, United States of America ^aff002; Department of Biobehavioral Nursing Science, University of Florida College of Nursing, Gainesville, Florida, United States of America ^aff003; Department of Biobehavioral Health Sciences, University of Illinois at Chicago College of Nursing, Chicago, Illinois, United States of America ^aff004; Committee on Clinical Pharmacology and Pharmacogenetics, University of Chicago, Chicago, Illinois, United States of America ^aff005; Department of Biopharmaceutical Sciences, University of Illinois at Chicago, Chicago, Illinois, United States of America ^aff006; Cancer Center, University of Illinois at Chicago, Chicago, Illinois, United States of America ^aff007; Division of Hematology/Oncology, University of Illinois at Chicago College of Medicine, Chicago, Illinois, United States of America ^aff008; Jessie Brown Veteran’s Administration Medical Center, Chicago, Illinois, United States of America ^aff009
Vyšlo v časopise: PLoS ONE 14(11)
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pone.0224886

Souhrn

Purpose

Frequencies of single nucleotide polymorphisms (SNPs) from pain related candidate genes are available for individuals with sickle cell disease (SCD). One of those genes, the arginine vasopressin receptor 1A gene (AVPR1A) and one of its SNPs, rs10877969, has been associated with pain and disability in other pain populations. In patients with SCD, clinical factors such as pain and stress have been associated with increased health care utilization, but it is not known if the presence of the AVPR1A SNP plays a role in this observation. The study purpose was to explore the relationships between rs10877969 and self-reported pain, stress, and acute care utilization events among individuals with SCD.

Methods

In a cross-sectional investigation of outpatients with SCD, participants completed PAINReportIt^®, a computerized pain measure, to describe their pain experience and contributed blood or saliva samples for genetic analysis. We extracted emergency department and acute care utilization from medical records.

Results

The SNP genotype frequencies (%) for this sample were CC 30 (28%), CT 44 (41%), TT 33 (31%). Acute care utilization and stress as an aggravator of pain were significantly associated with the rs10877969 genotype (p = .02 and p = .002, respectively). The CT genotype had the highest mean utilization and CC genotype was associated with not citing stress as a pain aggravator. Chronic pain was not associated with rs10877969 (p = .41).

Conclusion

This study shows that rs10877969 is related to indicators of stress and acute pain. Further research is recommended with other measures of stress and acute pain.

Klíčová slova:

Molecular genetics – Critical care and emergency medicine – Psychological stress – Outpatients – African American people – Vasopressin – Arginine – Sickle cell disease

Zdroje

1. Ezenwa MO, Molokie RE, Wang ZJ, Yao Y, Suarez ML, Angulo V, et al. Outpatient pain predicts subsequent one-year acute health care utilization among adults with sickle cell disease. J Pain Symptom Manage. 2014;48(1):65–74. doi: 10.1016/j.jpainsymman.2013.08.020 24636960; PubMed Central PMCID: PMC4082743.

2. Fillingim RB, Wallace MR, Herbstman DM, Ribeiro-Dasilva M, Staud R. Genetic contributions to pain: a review of findings in humans. Oral Dis. 2008;14(8):673–82. Epub 2009/02/06. doi: 10.1111/j.1601-0825.2008.01458.x 19193196; PubMed Central PMCID: PMC2667226.

3. Kim H, Neubert JK, San Miguel A, Xu K, Krishnaraju RK, Iadarola MJ, et al. Genetic influence on variability in human acute experimental pain sensitivity associated with gender, ethnicity and psychological temperament. Pain. 2004;109(3):488–96. doi: 10.1016/j.pain.2004.02.027 15157710

4. Lacroix-Fralish ML, Mogi JS. Progress in genetic studies of pain and analgesia. Annu Rev Pharmacol Toxicol. 2009;49(1):97–121. doi: 10.1146/annurev-pharmtox-061008-103222 18834308

5. Adegbola M. Genomics and pain research in sickle cell disease: an explanation of heterogeneity? ISRN Nurs. 2011;2011:672579. doi: 10.5402/2011/672579 21808743; PubMed Central PMCID: PMC3146762.

6. Ballas SK, Gupta K, Adams-Graves P. Sickle cell pain: a critical reappraisal. Blood. 2012;120(18):3647–56. Epub 2012/08/28. doi: 10.1182/blood-2012-04-383430 22923496.

7. Mogil JS. Pain genetics: past, present and future. Trends Genet. 2012;28(6):258–66. doi: 10.1016/j.tig.2012.02.004 22464640.

8. Jhun EH, Yao Y, He Y, Mack AK, Wilkie DJ, Molokie RE, et al. Prevalence of pain-related single nucleotide polymorphisms in patients of African origin with sickle cell disease. Pharmacogenomics. 2015;16(16):1795–806. Epub 2015/11/12. doi: 10.2217/pgs.15.126 26555434; PubMed Central PMCID: PMC4909047.

9. George SZ, Parr JJ, Wallace MR, Wu SS, Borsa PA, Dai Y, et al. Biopsychosocial influence on exercise-induced injury: genetic and psychological combinations are predictive of shoulder pain phenotypes. J Pain. 2014;15(1):68–80. doi: 10.1016/j.jpain.2013.09.012 24373571; PubMed Central PMCID: PMC3918888.

10. Kim-Shapiro DB, Gladwin MT. Nitric oxide pathology and therapeutics in sickle cell disease. Clin Hemorheol Microcirc. 2018;68(2–3):223–37. Epub 2018/04/05. doi: 10.3233/CH-189009 29614634; PubMed Central PMCID: PMC5911689.

11. Morris CR. Alterations of the arginine metabolome in sickle cell disease: a growing rationale for arginine therapy. Hematol Oncol Clin North Am. 2014;28(2):301–21. Epub 2014/03/05. doi: 10.1016/j.hoc.2013.11.008 24589268.

12. Morris CR, Kuypers FA, Larkin S, Sweeters N, Simon J, Vichinsky EP, et al. Arginine therapy: a novel strategy to induce nitric oxide production in sickle cell disease. Br J Haematol. 2000;111(2):498–500. doi: 10.1046/j.1365-2141.2000.02403.x PubMed PMID: WOS:000165827300016. 11122090

13. Bakshi N, Morris CR. The role of the arginine metabolome in pain: implications for sickle cell disease. J Pain Res. 2016;9:167–75. Epub 2016/04/22. doi: 10.2147/JPR.S55571 27099528; PubMed Central PMCID: PMC4821376.

14. Elias DBD, Barbosa MC, Rocha LBD, Dutra LLA, da Silva HF, Martins AMC, et al. L-arginine as an adjuvant drug in the treatment of sickle cell anaemia. Br J Haematol. 2013;160(3):410–2. doi: 10.1111/bjh.12114 PubMed PMID: WOS:000313746600018. 23157285

15. Lopez BL, Kreshak AA, Morris CR, Ballas SK, Davis-Moon L, Ma XL. Is L-arginine, the substrate for nitric oxide, altered in adult vasoocclusive sickle cell crisis? Blood. 2002;100(11):452a-a. PubMed PMID: WOS:000179184701753.

16. Lopez BL, Kreshak AA, Morris CR, Davis-Moon L, Ballas SK, Ma XL. L-arginine levels are diminished in adult acute vaso-occlusive sickle cell crisis in the emergency department. Br J Haematol. 2003;120(3):532–4. Epub 2003/02/13. doi: 10.1046/j.1365-2141.2003.04109.x 12580975.

17. Morris CR, Ansari M, Lavrisha L, Sweeters N, Kuypers FA, Vichinsky EP. L-Arginine: A Promising Nitric Oxide-Based Therapy for Vaso-Occlusive Pain Episodes in Sickle Cell Disease (SCD). Nitric Oxide-Biol Ch. 2010;22:S25–S6. doi: 10.1016/j.niox.2010.05.071 PubMed PMID: WOS:000278440700068.

18. Morris CR, Kuypers FA, Larkin S, Vichinsky EP, Styles LA. Patterns of arginine and nitric oxide in patients with sickle cell disease with vaso-occlusive crisis and acute chest syndrome. J Pediat Hematol Onc. 2000;22(6):515–20. doi: 10.1097/00043426-200011000-00009 PubMed PMID: WOS:000165933100008. 11132219

19. Jhun EH, Hu X, Sadhu N, Yao Y, He Y, Wilkie DJ, et al. Transient receptor potential polymorphism and haplotype associate with crisis pain in sickle cell disease. Pharmacogenomics. 2018;19(5):401–11. Epub 2018/04/06. doi: 10.2217/pgs-2017-0198 29620434.

20. Jhun EH, Sadhu N, Yao Y, He Y, Molokie RE, Wilkie DJ, et al. Glucocorticoid receptor single nucleotide polymorphisms are associated with acute crisis pain in sickle cell disease. Pharmacogenomics. 2018;19(13):1003–11. doi: 10.2217/pgs-2018-0064 30079801.

21. Ezenwa MO, Molokie RE, Wilkie DJ, Suarez ML, Yao Y. Perceived injustice predicts stress and pain in adults with sickle cell disease. Pain Manag Nurs. 2015;16(3):294–306. Epub 2014/12/03. doi: 10.1016/j.pmn.2014.08.004 25439119; PubMed Central PMCID: PMC4417102.

22. Brousseau DC, Owens PL, Mosso AL, Panepinto JA, Steiner CA. Acute care utilization and rehospitalizations for sickle cell disease. JAMA. 2010;303(13):1288–94. doi: 10.1001/jama.2010.378 20371788

23. Rees DC, Williams TN, Gladwin MT. Sickle-cell disease. Lancet. 2010;376(9757):2018–31. Epub 2010/12/07. doi: 10.1016/S0140-6736(10)61029-X 21131035.

24. Bakshi N, Ross D, Krishnamurti L. Presence of pain on three or more days of the week is associated with worse patient reported outcomes in adults with sickle cell disease. J Pain Res. 2018;11:313–8. Epub 2018/02/16. doi: 10.2147/JPR.S150065 29445298; PubMed Central PMCID: PMC5810514.

25. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988;16(3):1215. Epub 1988/02/11. doi: 10.1093/nar/16.3.1215 3344216; PubMed Central PMCID: PMC334765.

26. Molokie RE, Montminy C, Dionisio C, Farooqui MA, Gowhari M, Yao Y, et al. Opioid doses and acute care utilization outcomes for adults with sickle cell disease: ED versus acute care unit. Am J Emerg Med. 2018;36(1):88–92. doi: 10.1016/j.ajem.2017.07.037 28802541.

27. Jha A, Suarez ML, Ferrans CE, Molokie R, Ok Kim Y, Wilkie DJ. Cognitive Testing of PAINReportIt in Adult African Americans With Sickle Cell Disease. Comput Inform Nurs. 2010;28(3):141–50. doi: 10.1097/NCN.0b013e3181d7820b 20431356

28. Melzack R. The McGill Pain Questionnaire: Major properties and scoring methods. Pain. 1975;1(3):277–99. http://dx.doi.org/10.1016/0304-3959(75)90044-5 1235985

29. Wilkie DJ, Molokie R, Boyd-Seal D, Suarez ML, Kim YO, Zong S, et al. Patient-reported outcomes: descriptors of nociceptive and neuropathic pain and barriers to effective pain management in adult outpatients with sickle cell disease. J Natl Med Assoc. 2010;102(1):18–27. doi: 10.1016/s0027-9684(15)30471-5 20158132; PubMed Central PMCID: PMC3641147.

30. Wilkie DJ, Molokie RE, Suarez ML, Ezenwa MO, Wang ZJ. Composite Pain Index: Reliability, Validity, and Sensitivity of a Patient-Reported Outcome for Research: Composite Pain Index. Pain Med. 2015;16(7):1341–8. doi: 10.1111/pme.12703 25712169

31. Mogil JS, Sorge RE, LaCroix-Fralish ML, Smith SB, Fortin A, Sotocinal SG, et al. Pain sensitivity and vasopressin analgesia are mediated by a gene-sex-environment interaction. Nat Neurosci. 2011;14(12):1569–73. doi: 10.1038/nn.2941 22019732; PubMed Central PMCID: PMC3225498.

32. George SZ, Wu SS, Wallace MR, Moser MW, Wright TW, Farmer KW, et al. Biopsychosocial Influence on Shoulder Pain: Influence of Genetic and Psychological Combinations on Twelve-Month Postoperative Pain and Disability Outcomes. Arthritis Care Res (Hoboken). 2016;68(11):1671–80. Epub 2016/10/27. doi: 10.1002/acr.22876 26945673; PubMed Central PMCID: PMC5011032.

33. Gil KM, Carson JW, Porter LS, Scipio C, Bediako SM, Orringer E. Daily mood and stress predict pain, health care use, and work activity in African American adults with sickle-cell disease. Health Psychol. 2004;23(3):267–74. Epub 2004/04/22. doi: 10.1037/0278-6133.23.3.267 15099167.